The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.
about
Prognostic role of microRNA-145 in prostate cancer: A systems review and meta-analysisImplications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesisMicrornas in prostate cancer: an overview.miRNAs associated with prostate cancer risk and progressionHeterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlationsThe microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer.MicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer.Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies.miR-145 mediates the antiproliferative and gene regulatory effects of vitamin D3 by directly targeting E2F3 in gastric cancer cellsc-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell LineMutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.A Meta-Analysis: Identification of Common Mir-145 Target Genes that have Similar Behavior in Different GEO Datasets.MicroRNA-145 contributes to enhancing radiosensitivity of cervical cancer cells.Functional significance of aberrantly expressed microRNAs in prostate cancer.Prognostic and predictive biomarkers in prostate cancer.MiR-378 suppresses prostate cancer cell growth through downregulation of MAPK1 in vitro and in vivo.The roles of microRNAs in the progression of castration-resistant prostate cancer.Reciprocal regulation of PCGEM1 and miR-145 promote proliferation of LNCaP prostate cancer cells.MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer.MiRNA regulation of TRAIL expression exerts selective cytotoxicity to prostate carcinoma cells.Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line.Stability Assessment of Candidate Reference Genes in Urine Sediment of Prostate Cancer Patients for miRNA Applications.MicroRNA-143 acts as a tumor suppressor by targeting hexokinase 2 in human prostate cancer.Mir 145/143: tumor suppressor, oncogenic microenvironmental factor or ...both?Prognostic role of microRNA-145 in various human malignant neoplasms: a meta-analysis of 18 related studies.Uncovering the clinical utility of miR-143, miR-145 and miR-224 for predicting the survival of bladder cancer patients following treatment.Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies.Snail-activated long non-coding RNA PCA3 up-regulates PRKD3 expression by miR-1261 sponging, thereby promotes invasion and migration of prostate cancer cells.Regulation of NCAPG by miR-99a-3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC.Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention.A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer.
P2860
Q26782530-D642FE3C-2BCA-48FD-8553-6CCFE736B7E3Q26783563-8A4DC8A9-5CE7-40C3-B016-DD9A819B01BBQ30234658-FA1C79B0-C7DB-4C0B-9CDE-55A7E109F96DQ30235186-D88A3D77-E892-4F65-A41C-9433DE6FB35FQ33811802-0DEC2AA7-09F0-4EC5-9089-04B7BC329271Q34365861-D6967F3A-7982-4E8B-9159-D8406174E6C4Q34448246-0DCF696E-4588-4752-92F4-2830D6564ADCQ35082591-8289BF50-687C-4DA2-BB14-A98E76B1671DQ35781387-990DE79E-C585-414E-B926-F18C65860E1DQ35783276-5804B4C0-18E0-4E0C-8969-FD1BAB37BC66Q35896945-F8D9FDB7-C639-408F-8484-716D52D1965BQ36140097-EA2E5876-00F8-49FC-98F0-0ABCA006D1D2Q38301131-2DD13E71-6C30-4201-8F36-AF1E82389F1FQ38323461-D6B28AA4-D170-4491-AFFC-743592AF03C7Q38628081-623C5E65-448A-43B5-831A-070C37E3E207Q38837212-CDC89CDB-DE60-419C-A44B-C05E2E0AAA6FQ38859577-D274A23D-2FB9-4622-861C-F851A8BED3FFQ38958582-8A2C2037-FDDE-4038-BA1D-E8885DF191BBQ39016865-39DFFCE0-37E3-4C33-8CCF-6D00ACC01663Q39051553-016B6679-3FE9-49F2-8CF1-9FDF8AA7AD45Q39061591-E5238275-2FB3-4C46-BB42-D38AF0FF521CQ40288838-85CF162D-176D-4835-91A3-8A8320559653Q41947674-CE56FBC5-2386-4EDD-B4BA-B0694430FAC1Q42433774-B92763CE-3A1A-491A-83C6-F7898FE7E503Q43046143-4C8A2909-0AD7-42C0-9DCE-9404F2C4EA1BQ43717784-1138E501-809C-4E1F-B923-0873EE8C351EQ47109138-1A17101A-241B-4016-9F30-457F64771350Q47669687-10D1A531-4BE5-43DF-B066-475657E2FC6FQ51391966-70C02FB6-9D01-45E0-BBC1-47E3DAA9CB0FQ52334742-42A6D434-0C68-4850-9C82-CFEBFF3AAA18Q52718880-CE5853CE-D571-47DF-A04A-C7CB437CD3CAQ55045737-07E67650-C92F-40B9-9EF2-C0AA38F811C8
P2860
The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The loss of the tumour-suppres ...... l of prostate cancer patients.
@en
type
label
The loss of the tumour-suppres ...... l of prostate cancer patients.
@en
prefLabel
The loss of the tumour-suppres ...... l of prostate cancer patients.
@en
P2093
P2860
P356
P1476
The loss of the tumour-suppres ...... l of prostate cancer patients.
@en
P2093
E G Fragoulis
K Stravodimos
P2860
P2888
P304
P356
10.1038/BJC.2013.250
P407
P577
2013-05-23T00:00:00Z